Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022280 · ClinicalTrials.gov registry record · Phase 1
Effect of Proton Pump Inhibitors on Endothelial Function
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02022280: Completed Phase 1 study, sponsored by Stanford University.
NCT02022280 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02022280, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
In this randomized controlled crossover study, the investigators propose to test the hypothesis that proton pump inhibitors (PPIs) increase plasma levels of asymmetric dimethylarginine (ADMA), which is a marker of endothelial dysfunction. The authors propose to evaluate ADMA concentrations and vascular function analysis in healthy volunteers and adults with a history of cardiovascular disease given PPI vs placebo for four weeks each.
Interventions
- DRUG Placebo
- DRUG Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02022280
The ClinicalTrials.gov registry entry for NCT02022280 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02022280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02022280 about?
NCT02022280 is a clinical study titled "Effect of Proton Pump Inhibitors on Endothelial Function". In this randomized controlled crossover study, the investigators propose to test the hypothesis that proton pump inhibitors (PPIs) increase plasma levels of asymmetric dimethylarginine (ADMA), which is a marker of endothelial dysfunction. The authors propose to evaluate ADMA concentrations and vascu...
What is the current status of trial NCT02022280?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2013-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02022280?
The interventions under investigation include: Placebo (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT02022280?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.